Antengene (HKSE:06996) Other Operating Expense : HK$82.35 Mil (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Antengene Other Operating Expense?

Antengene's Other Operating Expense for the six months ended in Jun. 2024 was HK$56.45 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 was HK$82.35 Mil.

Antengene's quarterly Other Operating Expense declined from Jun. 2023 (HK$96.57 Mil) to Dec. 2023 (HK$-129.26 Mil) but then increased from Dec. 2023 (HK$-129.26 Mil) to Jun. 2024 (HK$56.45 Mil).

Antengene's annual Other Operating Expense increased from Dec. 2021 (HK$-29.35 Mil) to Dec. 2022 (HK$-11.64 Mil) but then declined from Dec. 2022 (HK$-11.64 Mil) to Dec. 2023 (HK$-32.68 Mil).

Antengene Other Operating Expense Historical Data

The historical data trend for Antengene's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Other Operating Expense Chart

Antengene Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Operating Expense

Get a 7-Day Free Trial

86.67

-29.35

-11.64

-32.68

81.88

Antengene Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Operating Expense	Get a 7-Day Free Trial								-111.91	96.57	-129.26	56.45	25.89

Antengene Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$82.35 Mil.

Antengene Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Antengene's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Antengene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

722:Germany

Address

1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN

Website

https://www.antengene.com

Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.

Executives

Mei Jay	2201 Interest of corporation controlled by you
Jay Mei 2023 Grat	2201 Interest of corporation controlled by you
Begonia Investment Ltd.	2101 Beneficial owner
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited	2301 Trustee
Tct (bvi) Limited	2501 Other
Fountainvest China Capital Partners Gp3 Ltd.	2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Fund Iii, L.p.	2201 Interest of corporation controlled by you
Fmr Llc	2201 Interest of corporation controlled by you
Fidelity Investment Trust	2101 Beneficial owner
Jay Mei 2020 Grat	2201 Interest of corporation controlled by you
Meiland Pharma Tech Spc
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd
Boyu Capital General Partner Iii, L.p.

Antengene Headlines

No Headlines